Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 17, Issue 4

July-August 2020

In this Issue

Diffusion
Features
Headlines from Washington
Image Challenge
Mini Review
No Data Zone
Op Ed
President’s Column

Diffusion

Ruxolitinib: A Long-Awaited Standard for Steroid Refractory Acute Graft-Versus-Host Disease

Hany Elmariah, MD, MS,Frederick Locke, MD

View Articletitled, Ruxolitinib: A Long-Awaited Standard for Steroid Refractory Acute Graft-Versus-Host Disease

CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations

Alexander Ambinder, MD, MPH,Amy DeZern, MD, MHS

View Articletitled, CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations

Trigger Unhappy? New Evidence Supports Mental Stress Can Trigger Microvascular Occlusion and Potentially Lead to Sickle Cell Pain Crisis

Ifeyinwa (Ify) Osunkwo, MD, MPH

View Articletitled, Trigger Unhappy? New Evidence Supports Mental Stress Can Trigger Microvascular Occlusion and Potentially Lead to Sickle Cell Pain Crisis

Complements and Catastrophe: How Complement Activation Affects Clinical Phenotype in Antiphospholipid Syndrome

Eric Tseng, MD, MScCH, FRCPC

View Articletitled, Complements and Catastrophe: How Complement Activation Affects Clinical Phenotype in Antiphospholipid Syndrome

Pan-cancer Genome Analysis: In the Clouds?

Giulia Orlando, PhD,Adam Mead, MD, PhD

View Articletitled, Pan-cancer Genome Analysis: In the Clouds?

Quantified Morphology in Diagnosis of Hematologic Malignancies

Mahshid Rahmat, PhD,Irene M. Ghobrial, MD

View Articletitled, Quantified Morphology in Diagnosis of Hematologic Malignancies

More Options for Cancer-associated Thrombosis: Apixaban Non-inferior to Dalteparin

Robert D. McBane, II, MD,Damon Houghton, MD

View Articletitled, More Options for Cancer-associated Thrombosis: Apixaban Non-inferior to Dalteparin

Allogeneic HSCT After PD-1 Blockade: Has Post-transplant Cyclophosphamide Rendered Checkpoint Inhibition a Safe Bridge to Allogeneic Stem Cell Transplantation?

Ash B. Alpert, MD, MFA,Kristen M. O'Dwyer, MD

View Articletitled, Allogeneic HSCT After PD-1 Blockade: Has Post-transplant Cyclophosphamide Rendered Checkpoint Inhibition a Safe Bridge to Allogeneic Stem Cell Transplantation?

Unmasking the Immunopathological Characteristics of COVID-19: Monocytes Grow With the Flow and Lymphocytes Shelter in Place?

Daniel DiToro, MD, PhD,Annette S. Kim, MD, PhD

View Articletitled, Unmasking the Immunopathological Characteristics of COVID-19: Monocytes Grow With the Flow and Lymphocytes Shelter in Place?

Taking the Brakes Off Programmed Cell Death: Will It Work for AML in Older Patients?

Claudia Bruedigam, PhD,Steven Lane, MBBS, PhD, FRACP, FRCPA

View Articletitled, Taking the Brakes Off Programmed Cell Death: Will It Work for AML in Older Patients?

Features

Hematologic Therapies Being Studied for Coronavirus: Capitalizing on Progress

Laura C. Michaelis, MD,Kathleen Monahan, DO

View Articletitled, Hematologic Therapies Being Studied for Coronavirus: Capitalizing on Progress

Headlines from Washington

ASH Members Respond to COVID-19 Challenges

ASH Staff

View Articletitled, ASH Members Respond to COVID-19 Challenges

Image Challenge

Spots and Dots

Olga Pozdnyakova, MD, PhD,Annette S. Kim, MD, PhD

View Articletitled, Spots and Dots

Mini Review

Convalescent Plasma for COVID-19: An Old Therapy for a Novel Pathogen

Caroline Diorio, MD, FRCPC, FAAP,David T. Teachey, MD,Hamid Bassiri, MD, PhD

View Articletitled, Convalescent Plasma for COVID-19: An Old Therapy for a Novel Pathogen

The Challenge We Face: Sickle Cell Disease and the COVID-19 Pandemic

Ahmar U. Zaidi, MD,Caterina P. Minniti, MD

View Articletitled, The Challenge We Face: Sickle Cell Disease and the COVID-19 Pandemic

No Data Zone

The COVID Coagulopathy Conundrum: Facts, Fiction, and Fantasy

Agnes Lee, MD, MSc, FRCPC,Lisa Baumann Kreuziger, MD, MS

View Articletitled, The COVID Coagulopathy Conundrum: Facts, Fiction, and Fantasy

Op Ed

Mye-llennial Dilemma: What Are the Optimal Endpoints for Multiple Myeloma Clinical Trials?

Shebli Atrash, MD,Saad Usmani, MD

View Articletitled, Mye-llennial Dilemma: What Are the Optimal Endpoints for Multiple Myeloma Clinical Trials?

President’s Column

The New Normal

Stephanie Lee, MD, MPH

View Articletitled, The New Normal

Cover Image

Cover Image

All Issues

Advertisement intended for health care professionals

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read

Targeting the Natural History of Clonal Hematopoiesis

Ph- MPN in Adolescent and Young Adult Patients

An Australian Perspective on Bone Marrow Examination as a Standard Requirement for Hematology Trainees

ASH Committee Supports Care for Sickle Cell Disease on Capitol Hill

Colleagues Reflect on Legacy of Groundbreaking Hematologist Connie J. Eaves

Advertisement intended for health care professionals

Table of Contents

Diffusion

Ruxolitinib: A Long-Awaited Standard for Steroid Refractory Acute Graft-Versus-Host Disease

CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations

Trigger Unhappy? New Evidence Supports Mental Stress Can Trigger Microvascular Occlusion and Potentially Lead to Sickle Cell Pain Crisis

Complements and Catastrophe: How Complement Activation Affects Clinical Phenotype in Antiphospholipid Syndrome

Pan-cancer Genome Analysis: In the Clouds?

Quantified Morphology in Diagnosis of Hematologic Malignancies

More Options for Cancer-associated Thrombosis: Apixaban Non-inferior to Dalteparin

Allogeneic HSCT After PD-1 Blockade: Has Post-transplant Cyclophosphamide Rendered Checkpoint Inhibition a Safe Bridge to Allogeneic Stem Cell Transplantation?

Unmasking the Immunopathological Characteristics of COVID-19: Monocytes Grow With the Flow and Lymphocytes Shelter in Place?

Taking the Brakes Off Programmed Cell Death: Will It Work for AML in Older Patients?

Features

Hematologic Therapies Being Studied for Coronavirus: Capitalizing on Progress

Headlines from Washington

ASH Members Respond to COVID-19 Challenges

Image Challenge

Spots and Dots

Mini Review

Convalescent Plasma for COVID-19: An Old Therapy for a Novel Pathogen

The Challenge We Face: Sickle Cell Disease and the COVID-19 Pandemic

No Data Zone

The COVID Coagulopathy Conundrum: Facts, Fiction, and Fantasy

Op Ed

Mye-llennial Dilemma: What Are the Optimal Endpoints for Multiple Myeloma Clinical Trials?

President’s Column

The New Normal

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Diffusion

Features

Headlines from Washington

Image Challenge

Mini Review

No Data Zone

Op Ed

President’s Column

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only